A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497–501., .
Chromosomal localization of human cellular homologues of two viral oncogenes. Nature 1982;299(5885):747–9., , et al.
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247(4944):824–30., , .
Chronic myeloid leukemia – advances in biology and new approaches to treatment. New Engl J Med 2003;349(15):1451–64., .
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2(5):561–6., , et al.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003;348(11):994–1004., , et al.
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99(10):3530–9., , et al.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001;344(14):1031–7., , et al.
Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008:32–7., , , . Chronic myelogenous leukaemia, BCR-ABL1 positive. In , , , (eds.),
Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131(3):207–19., , , .
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 2005;19(6):984–9., , et al.
Chronic myelogenous leukemia and exposure to ionizing radiation – a retrospective study of 443 patients. Ann Hematol 1995;70(2):79–82., , et al.
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia 2003;17(12):2474–86., , et al.
Consistent amounts of acute leukemia-associated P190 BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood 1996;87(3):1075–80., , et al.
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88(7):2375–84..
P190 BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?Leukemia 1994;8(1):208–11., , , .
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996;88(7):2410–14., , et al.
Chronic myeloid leukaemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27(35):6041–51., , et al.
Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984;63(4):789–99., , et al.
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90(11):850–8., , et al.
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 2003;88(3):256–9., , et al.
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. Semin Hematol 2003;40(1):4–12., , et al.
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98(10):3074–81., , et al.
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med 2006;355(23):2408–17., , et al.
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003;17(12):2401–9., , et al.
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?Cancer 2008;112(4):837–45., , et al.
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108(5):1478–84., , et al.
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 2003;98(12):2636–42., , et al.
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006;108(6):1835–40., , et al.
Outcome, prognostic factors and long-term follow-up in 207 chronic phase CML patients receiving front-line imatinib 400 mg at a single institution. ASH Annual Meeting Abstr 2007;110(11):1045., , et al.
A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008;22(10):1963–6., , et al.
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103(8):2873–8., , et al.
A phase iii, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (im) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study. ASH Annual Meeting Abstr 2008;112(11):335., , et al.
Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). ASH Annual Meeting Abstr 2008;112(11):446., , et al.
Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). ASH Annual Meeting Abstr 2008;112(11):182., , et al.
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26(20):3358–63., , et al.
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8(11):1018–29..
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94(5):1517–36., , et al.
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352(9134):1087–92., , et al.
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106(9):2969–76., , et al.
How I treat chronic myeloid leukemia in the imatinib era. Blood 2007;110(8):2828–37..
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New Engl J Med 2003;349(15):1423–32., , et al.
Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia. Hum Pathol 2005;36(1):91–100., , et al.
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101(10):3794–800., , et al.
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101(5):1941–9., , et al.
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003;17(3):481–7., , et al.
Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 2005;19(3):460–3., , et al.
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007;110(7):1509–19., , et al.
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108(1):28–37., , et al.
International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res 2008;32(3):505–6., , , .
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293(5531):876–80., , et al.
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2(2):117–25., , et al.
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99(9):3472–5., , et al.
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359(9305):487–91., , , .
BCR-ABL kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110(7):2242–9., , .
First-line therapy for chronic myeloid leukemia: past, present, and future. Am J Hematol 2009;84(5):287–93., , .
Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004;18(3):641–56, ix., .
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009;114(13):2598–605., , , , .
In chronic myeloid leukemia (CML) patients with complete cytogenetic response to imatinib, BCR-ABL kinase domain mutations are relatively rare and not consistently associated with subsequent relapse. ASH Annual Meeting Abstr 2005;106(11):434., , et al.
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20(10):1767–73., , et al.
Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91(4):513–21., , et al.
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008;111(4):1774–80., , , .